Associate Professor Simone M Goldinger
Associate Professor and Senior Principal Research Fellow
Frazer Institute
Researcher biography
A/ Professor Simone M Goldinger is a clinician-researcher in dermatology with a subspecialty focus on skin cancer and digital health. Her work sits at the intersection of clinical dermatology, artificial intelligence, and longitudinal imaging, with a particular emphasis on non-melanoma skin cancer detection and surveillance. Her current research develops and validates equitable, data-driven approaches to skin cancer diagnosis, drawing on large-scale longitudinal datasets to improve accuracy, address algorithmic bias, and support real-world clinical implementation. A central goal is ensuring these AI-powered tools are effective across diverse patient populations and translatable into everyday clinical practice.
Earlier in her career, A/Prof Goldinger specialised in dermato-oncology, focusing on metastatic melanoma and the cutaneous toxicities associated with immune checkpoint inhibitors and targeted therapies. This background in advanced disease management provides a strong translational foundation for her current work, connecting insights from late-stage oncology to earlier detection, risk stratification, and long-term monitoring. Her research bridges clinical medicine, data science, and health equity — with the aim of improving outcomes for patients with skin cancer in Australia and beyond.
Journal Articles
Hussain, Nurul Amanina Binte, King, Abigail, Horsham, Caitlin, Goldinger, Simone M. and Janda, Monika (2026). Evolving landscape of consumer‐based smartphone apps for skin cancer prevention and early detection. Journal of the European Academy of Dermatology and Venereology jdv.70464. doi: 10.1111/jdv.70464
Susanto, Alyssa, Primiero, Clare, Goldinger, Simone M., Soyer, H. Peter and Janda, Monika (2025). The impact of multidisciplinary research on progress in skin cancer prevention. Cancers, 17 (21) 3473, 1-21. doi: 10.3390/cancers17213473
Susanto, Alyssa, Kahler, Sam, Dulanjala Sewwandi, M. A. Nayomi, Mothershaw, Adam, Goldinger, Simone M., Mar, Victoria, Janda, Monika, Soyer, H.Peter and Primiero, Clare (2025). Three-dimensional total body photography enables automated obesity-related comorbidity screening in dermatology. Journal of Investigative Dermatology, 146 (3), 855-858. doi: 10.1016/j.jid.2025.09.001
von Bubnoff, Dagmar, Schmitt, Christina, Goldinger, Simone M., Schadendorf, Dirk, Kaehler, Katharina C., Hafner, Christian, Kramer, Nora, Froehlich, Waltraud, Dummer, Reinhard, Berking, Carola, Schliep, Stefan, Kirchberger, Michael C. and Heinzerling, Lucie (2025). Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab. PLoS One, 20 (5) e0321937, 1-15. doi: 10.1371/journal.pone.0321937
Pham, James P., Staeger, Ramon, Joshua, Anthony M., Liu, Jia, da Silva, Ines P., Dummer, Reinhard and Goldinger, Simone M. (2025). An updated review of immune checkpoint inhibitors in cutaneous oncology: beyond melanoma. European Journal of Cancer, 214 115121, 1-11. doi: 10.1016/j.ejca.2024.115121
Pham, James P., Kondo, Mickey, Hurwitz, Joshua, Cosman, Rasha, Goldinger, Simone M., Dummer, Reinhard, Sim, Hao-Wen and Joshua, Anthony M. (2025). Efficacy of immune checkpoint inhibitors in advanced mucosal melanoma: a systematic review and meta-analysis. EJC Skin Cancer, 3 100756. doi: 10.1016/j.ejcskn.2025.100756
Pham, James P., Rodrigues, Anthony, Goldinger, Simone M., Sim, Hao‐Wen and Liu, Jia (2024). Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: a systematic review and meta‐analysis. Experimental Dermatology, 33 (1) e14978, 1-7. doi: 10.1111/exd.14978
Pham, James P., Joshua, Anthony M., da Silva, Ines P., Dummer, Reinhard and Goldinger, Simone M. (2023). Chemotherapy in cutaneous melanoma: is there still a role?. Current Oncology Reports, 25 (6), 609-621. doi: 10.1007/s11912-023-01385-6
Truong, Kelvin, Goldinger, Simone M., Chou, Shaun, Howle, Julie R., Veness, Michael J., Fernandez‐Peñas, Pablo and Varey, Alexander H. R. (2022). Merkel cell carcinoma in situ: a systematic review of prognosis and management. Australasian Journal of Dermatology, 63 (1), e6-e12. doi: 10.1111/ajd.13758
Goldinger, Simone M., Buder-Bakhaya, Kristina, Lo, Serigne N., Forschner, Andrea, McKean, Meredith, Zimmer, Lisa, Khoo, Chloe, Dummer, Reinhard, Eroglu, Zeynep, Buchbinder, Elizabeth I., Ascierto, Paolo A., Gutzmer, Ralf, Rozeman, Elisa A., Hoeller, Christoph, Johnson, Douglas B., Gesierich, Anja, Kölblinger, Peter, Bennannoune, Naima, Cohen, Justine V., Kähler, Katharina C., Wilson, Melissa A., Cebon, Jonathan, Atkinson, Victoria, Smith, Jessica L., Michielin, Olivier, Long, Georgina V., Hassel, Jessica C., Weide, Benjamin, Haydu, Lauren E. ... Menzies, Alexander M. (2022). Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 162, 22-33. doi: 10.1016/j.ejca.2021.11.022
Truong, K., Goldinger, S., Kim, J., Smith, A. and Fernandez-Penas, P. (2021). Toxic epidermal necrolysis-like lupus erythematosus: a condition to exclude in all patients with possible Stevens-Johnson syndrome/toxic epidermal necrolysis. Journal of the European Academy of Dermatology and Venereology, 36 (3), E218-E221. doi: 10.1111/jdv.17753
Knispel, Sarah, Gassenmaier, Maximilian, Menzies, Alexander M., Loquai, Carmen, Johnson, Douglas B., Franklin, Cindy, Gutzmer, Ralf, Hassel, Jessica C., Weishaupt, Carsten, Eigentler, Thomas, Schilling, Bastian, Schummer, Patrick, Sirokay, Judith, Kiecker, Felix, Owen, Carina N., Fleischer, Maria, Cann, Christopher, Kaehler, Katharina C., Mohr, Peter, Bluhm, Leonie, Niebel, Dennis, Thoms, Kai-Martin, Goldinger, Simone M., Reinhardt, Lydia, Meier, Friedegund, Berking, Carola, Reinhard, Raphael, Susok, Laura, Ascierto, Paolo A. ... Zimmer, Lisa (2021). Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 148, 61-75. doi: 10.1016/j.ejca.2021.01.034
Matter, Alexandra Valeska, Micaletto, Sara, Urner-Bloch, Ursula, Dummer, Reinhard and Goldinger, Simone M. (2020). Long-term response to intermittent binimetinib in patients with NRAS-mutant melanoma. Oncologist, 25 (11), E1593-E1597. doi: 10.1634/theoncologist.2019-0656
Liu, David, Schilling, Bastian, Liu, Derek, Sucker, Antje, Livingstone, Elisabeth, Jerby-Arnon, Livnat, Zimmer, Lisa, Gutzmer, Ralf, Satzger, Imke, Loquai, Carmen, Grabbe, Stephan, Vokes, Natalie, Margolis, Claire A., Conway, Jake, He, Meng Xiao, Elmarakeby, Haitham, Dietlein, Felix, Miao, Diana, Tracy, Adam, Gogas, Helen, Goldinger, Simone M., Utikal, Jochen, Blank, Christian U., Rauschenberg, Ricarda, von Bubnoff, Dagmar, Krackhardt, Angela, Weide, Benjamin, Haferkamp, Sebastian, Kiecker, Felix ... Schadendorf, Dirk (2020). Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (vol 25, pg 1915, 2019). Nature Medicine, 26 (7), 1147-1147. doi: 10.1038/s41591-020-0975-4
Liu, David, Schilling, Bastian, Liu, Derek, Sucker, Antje, Livingstone, Elisabeth, Jerby-Amon, Livnat, Zimmer, Lisa, Gutzmer, Ralf, Satzger, Imke, Loquai, Carmen, Grabbe, Stephan, Vokes, Natalie, Margolis, Claire A., Conway, Jake, He, Meng Xiao, Elmarakeby, Haitham, Dietlein, Felix, Miao, Diana, Tracy, Adam, Gogas, Helen, Goldinger, Simone M., Utikal, Jochen, Blank, Christian U., Rauschenberg, Ricarda, von Bubnoff, Dagmar, Krackhardt, Angela, Weide, Benjamin, Haferkamp, Sebastian, Kiecker, Felix ... Schadendorf, Dirk (2019). Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine, 25 (12), 1916-1927. doi: 10.1038/s41591-019-0654-5
Goldinger, S. M., Valeska Matter, A., Urner‐Bloch, U., Narainsing, J., Micaletto, S., Blume, I., Mangana, J. and Dummer, R. (2019). Binimetinib in heavily pretreated patients with NRAS‐mutant melanoma with brain metastases. British Journal of Dermatology, 182 (2), 488-490. doi: 10.1111/bjd.18449
Johnson, Douglas B., McDonnell, Wyatt J., Gonzalez-Ericsson, Paula I., Al-Rohil, Rami N., Mobley, Bret C., Salem, Joe-Elie, Wang, Daniel Y., Sanchez, Violeta, Wang, Yu, Chastain, Cody A., Barker, Kristi, Liang, Yan, Warren, Sarah, Beechem, Joseph M., Menzies, Alexander M., Tio, Martin, Long, Georgina V., Cohen, Justine V., Guidon, Amanda C., O'Hare, Meabh, Chandra, Sunandana, Chowdhary, Akansha, Lebrun-Vignes, Benedicte, Goldinger, Simone M., Rushing, Elisabeth J., Buchbinder, Elizabeth I., Mallal, Simon A., Shi, Chanjuan, Xu, Yaomin ... Balko, Justin M. (2019). A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Medicine, 25 (8), 1243-1250. doi: 10.1038/s41591-019-0523-2
Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Foppen, M. H. Geukes, Hoejberg, L., Schmidt, H., van Thienen, J., Haanen, J. B. A. G., Tiainen, L., Svane, I. M., Makela, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A. M., Long, G., Atkinson, V., Blank, C. U. and Neyns, B. (2019). Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology, 30 (7), 1154-1161. doi: 10.1093/annonc/mdz110
Graf, N. P., Koelblinger, P., Galliker, N., Conrad, S., Barysch, M., Mangana, J., Dummer, R., Cheng, P. F. and Goldinger, S. M. (2019). The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. Journal of the European Academy of Dermatology and Venereology, 33 (4), 686-692. doi: 10.1111/jdv.15363
Schilling, Bastian, Martens, Alexander, Foppen, Marnix H. Geukes, Gebhardt, Christoffer, Hassel, Jessica C., Rozeman, Elisa A., Gesierich, Anja, Gutzmer, Ralf, Kaehler, Katharina C., Livingstone, Elisabeth, Diamantopoulos, Panagiotis T., Gogas, Helen, Madonna, Gabriele, Ascierto, Paolo A., Goldinger, Simone M., Mangana, Johanna, Garbe, Claus, Schadendorf, Dirk, Blank, Christian and Weide, Benjamin (2019). First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. Cancer Immunology Immunotherapy, 68 (5), 765-772. doi: 10.1007/s00262-019-02311-1
Drago, Joshua Z., Lawrence, Donald, Livingstone, Elisabeth, Zimmer, Lisa, Chen, Tianqi, Giobbie-Hurder, Anita, Amann, Valerie C., Mangana, Joanna, Siano, Marco, Zippelius, Alfred, Dummer, Reinhard, Goldinger, Simone M. and Sullivan, Ryan J. (2019). Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. Melanoma Research, 29 (1), 65-69. doi: 10.1097/CMR.0000000000000527
Hogan, Sabrina A., Courtier, Anais, Cheng, Phil F., Jaberg-Bentele, Nicoletta F., Goldinger, Simone M., Manuel, Manuarii, Perez, Solene, Plantier, Nadia, Mouret, Jean-Francois, Thi Dan Linh Nguyen-Kim,, Raaijmakers, Marieke I. G., Kvistborg, Pia, Pasqual, Nicolas, Haanen, John B. A. G., Dummer, Reinhard and Levesque, Mitchell P. (2019). Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma. Cancer Immunology Research, 7 (1), 77-85. doi: 10.1158/2326-6066.CIR-18-0136
Tio, Martin, Rai, Rajat, Ezeoke, Ogochukwu M., McQuade, Jennifer L., Zimmer, Lisa, Khoo, Chloe, Park, John J., Spain, Lavinia, Turajlic, Samra, Ardolino, Luke, Yip, Desmond, Goldinger, Simone M., Cohen, Justine V., Millward, Michael, Atkinson, Victoria, Kane, Alisa Y., Ascierto, Paolo A., Garbe, Claus, Gutzmer, Ralf, Johnson, Douglas B., Rizvi, Hira A., Joshua, Anthony M., Hellmann, Matthew D., Long, Georgina V. and Menzies, Alexander M. (2018). Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. European Journal of Cancer, 104, 137-144. doi: 10.1016/j.ejca.2018.09.017
Dimitriou, Florentia, Krattinger, Regina, Ramelyte, Egle, Barysch, Marjam J., Micaletto, Sara, Dummer, Reinhard and Goldinger, Simone M. (2018). The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. Current Oncology Reports, 20 (11) 87. doi: 10.1007/s11912-018-0732-8
Dummer, Reinhard, Michielin, Olivier, Nageli, Mirjam Chantal, Goldinger, Simone M., Campigotto, Federico, Kriemler-Krahn, Ulrike, Schmid, Herbert, Pedroncelli, Alberto, Micaletto, Sara and Schadendorf, Dirk (2018). Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma. Esmo Open, 3 (5) UNSP e000388. doi: 10.1136/esmoopen-2018-000388
Dimitriou, Florentia, Frauchiger, Anna L., Urosevic-Maiwald, Mirjana, Naegeli, Mirjam C., Goldinger, Simone M., Barysch, Marjam, Franzen, Daniel, Kamarachev, Jivko, Braun, Ralph, Dummer, Reinhard and Mangana, Joanna (2018). Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Research, 28 (3), 230-236. doi: 10.1097/CMR.0000000000000437
Valpione, Sara, Carlino, Matteo S., Mangana, Johanna, Mooradian, Meghan J., McArthur, Grant, Schadendorf, Dirk, Hauschild, Axel, Menzies, Alexander M., Arance, Ana, Ascierto, Paolo A., Di Giacomo, AnnaMaria, de Rosa, Francesco, Larkin, James, Park, John J., Goldinger, Simone M., Sullivan, Ryan J., Xu, Wen, Livingstone, Elisabeth, Weichenthal, Michael, Rai, Rajat, Gaba, Lydia, Long, Georgina V. and Lorigan, Paul (2018). Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study (vol 91, pg 116, 2018). European Journal of Cancer, 93, 158-158. doi: 10.1016/j.ejca.2018.02.001
Hecht, Markus, Meier, Friedegund, Zimmer, Lisa, Polat, Bulent, Loquai, Carmen, Weishaupt, Carsten, Forschner, Andrea, Gutzmer, Ralf, Utikal, Jochen S., Goldinger, Simone M., Geier, Michael, Hassel, Jessica C., Balermpas, Panagiotis, Kiecker, Felix, Rauschenberg, Ricarda, Dietrich, Ursula, Clemens, Patrick, Berking, Carola, Grabenbauer, Gerhard, Schadendorf, Dirk, Grabbe, Stephan, Schuler, Gerold, Fietkau, Rainer, Distel, Luitpold V. and Heinzerling, Lucie (2018). Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. British Journal of Cancer, 118 (6), 785-792. doi: 10.1038/bjc.2017.489
Valpione, Sara, Carlino, Matteo S., Mangana, Johanna, Mooradian, Meghan J., McArthur, Grant, Schadendorf, Dirk, Hauschild, Axel, Menzies, Alexander M., Arance, Ana, Ascierto, Paolo A., Di Giacomo, AnnaMaria, de Rosa, Francesco, Larkin, James, Park, John J., Goldinger, Simone M., Sullivan, Ryan J., Xu, Wen, Livingstone, Elisabeth, Weichenthal, Michael, Rai, Rajat, Gaba, Lydia, Long, Georgina V. and Lorigan, Paul (2018). Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. European Journal of Cancer, 91, 116-124. doi: 10.1016/j.ejca.2017.12.007
Krahenbuhl, Lukas, Goldinger, Simone M., Mangana, Joanna, Kerl, Katrin, Chevolet, Ines, Brochez, Lieve, Horak, Christine, Levesque, Mitch, Dummer, Reinhard and Cheng, Phil F. (2018). A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. Neoplasia, 20 (2), 218-225. doi: 10.1016/j.neo.2017.12.002
Braun, Ralph P., Mangana, Johanna, Goldinger, Simone, French, Lars, Dummer, Reinhard and Marghoob, Ashfaq A. (2017). Electrical Impedance Spectroscopy in Skin Cancer Diagnosis. Dermatologic Clinics, 35 (4), 489-+. doi: 10.1016/j.det.2017.06.009
Brueggemann, C., Kirchberger, M. C., Goldinger, S. M., Weide, B., Konrad, A., Erdmann, M., Schadendorf, D., Croner, R. S., Krahenbuhl, L., Kaehler, K. C., Hafner, C., Leisgang, W., Kiesewetter, F., Dummer, R., Schuler, G., Stuerzl, M. and Heinzerling, L. (2017). Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Journal of Cancer Research and Clinical Oncology, 143 (10), 1977-1984. doi: 10.1007/s00432-017-2450-2
Amann, V. C., Hoffmann, D., Mangana, J., Dummer, R. and Goldinger, S. M. (2017). Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma. Journal of the European Academy of Dermatology and Venereology, 31 (10), 1638-1640. doi: 10.1111/jdv.14268
Izar, Benjamin, Sharfman, William, Hodi, F. Stephen, Lawrence, Donald, Flaherty, Keith T., Amaravadi, Ravi, Kim, Kevin B., Puzanov, Igor, Sosman, Jeffrey, Dummer, Reinhard, Goldinger, Simone M., Lam, Lyhping, Kakar, Shefali, Tang, Zhongwen, Krieter, Oliver, McDermott, David F. and Atkins, Michael B. (2017). A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Medicine, 6 (8), 1904-1914. doi: 10.1002/cam4.1140
Frauchiger, Anna L., Bruggen, Marie-Charlotte, Goldinger, Simone M. and Dummer, Reinhard (2017). Interstitial granulomatous dermatitis during talimogen laherparepvec treatment. Melanoma Research, 27 (4), 400-401. doi: 10.1097/CMR.0000000000000369
Mangana, Joanna, Cheng, Phil F., Kaufmann, Corina, Amann, Valerie C., Frauchiger, Anna L., Stoegner, Viola, Held, Ulrike, von Moos, Roger, Michielin, Olivier, Braun, Ralph P., Levesque, Mitchell P., Goldinger, Simone M. and Dummer, Reinhard (2017). Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Research, 27 (4), 358-368. doi: 10.1097/CMR.0000000000000359
Murer, Carla, Kranzlin-Stieger, Pascale, French, Lars E., Dummer, Reinhard and Goldinger, Simone M. (2017). Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report. Melanoma Research, 27 (4), 396-398. doi: 10.1097/CMR.0000000000000358
Bossart, Simon, Thurneysen, Selina, Rushing, Elisabeth, Frontzek, Karl, Leske, Henning, Mihic-Probst, Daniela, Nagel, Hannes W., Mangana, Johanna, Goldinger, Simone M. and Dummer, Reinhard (2017). Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma. Oncologist, 22 (6), 749-753. doi: 10.1634/theoncologist.2016-0366
Haueis, Silvia A., Kranzlin, Pascale, Mangana, Joanna, Cheng, Phil F., Urosevic-Maiwald, Mirjana, Braun, Ralph P., Levesque, Mitchell P., Dummer, Reinhard and Goldinger, Simone M. (2017). Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?. Melanoma Research, 27 (3), 231-237. doi: 10.1097/CMR.0000000000000338
Kaufmann, Fabrice and Goldinger, Simone M. (2017). Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma. International Journal of Radiation Oncology Biology Physics, 98 (1), 15-16. doi: 10.1016/j.ijrobp.2017.01.245
Tumeh, Paul C., Hellmann, Matthew D., Hamid, Omid, Tsai, Katy K., Loo, Kimberly L., Gubens, Matthew A., Rosenblum, Michael, Harview, Christina L., Taube, Janis M., Handley, Nathan, Khurana, Neharika, Nosrati, Adi, Krummel, Matthew F., Tucker, Andrew, Sosa, Eduardo V., Sanchez, Phillip J., Banayan, Nooriel, Osorio, Juan C., Nguyen-Kim, Dan L., Chang, Jeremy, Shintaku, I. Peter, Boasberg, Peter D., Taylor, Emma J., Munster, Pamela N., Algazi, Alain P., Chmielowski, Bartosz, Dummer, Reinhard, Grogan, Tristan R., Elashoff, David ... Daud, Adil (2017). Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunology Research, 5 (5), 417-424. doi: 10.1158/2326-6066.CIR-16-0325
Nosrati, Adi, Tsai, Katy K., Goldinger, Simone M., Tumeh, Paul, Grimes, Barbara, Loo, Kimberly, Algazi, Alain P., Thi Dan Linh Nguyen-Kim, , Levesque, Mitchell, Dummer, Reinhard, Hamid, Omid and Daud, Adil (2017). Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. British Journal of Cancer, 116 (9), 1141-1147. doi: 10.1038/bjc.2017.70
Zimmer, Lisa, Apuri, Susmitha, Eroglu, Zeynep, Kottschade, Lisa A., Forschner, Andrea, Gutzmer, Ralf, Schlaak, Max, Heinzerling, Lucie, Krackhardt, Angela M., Loquai, Carmen, Markovic, Svetomir N., Joseph, Richard W., Markey, Kelly, Utikal, Jochen S., Weishaupt, Carsten, Goldinger, Simone M., Sondak, Vernon K., Zager, Jonathan S., Schadendorf, Dirk and Khushalani, Nikhil I. (2017). Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. European Journal of Cancer, 75, 47-55. doi: 10.1016/j.ejca.2017.01.009
Heinzerling, Lucie and Goldinger, Simone M. (2017). A review of serious adverse effects under treatment with checkpoint inhibitors. Current Opinion in Oncology, 29 (2), 136-144. doi: 10.1097/CCO.0000000000000358
Dummer, Reinhard, Ramelyte, Egle, Levesque, Mitch, Goldinger, Simone M. and Braun, Ralph P. (2017). Critical aspects to achieve a high-quality melanoma clinic. Current Opinion in Oncology, 29 (2), 145-150. doi: 10.1097/CCO.0000000000000357
Amann, V. C., Ramelyte, E., Thurneysen, S., Pitocco, R., Bentele-Jaberg, N., Goldinger, S. M., Dummer, R. and Mangana, J. (2017). Developments in targeted therapy in melanoma. Ejso, 43 (3), 581-593. doi: 10.1016/j.ejso.2016.10.014
Thurneysen, S., Cheng, P. F., Nagel, H. W., Kunz, M., Jaberg-Bentele, N., Nageli, M., Ziegler, M., Guenova, E., Goldinger, S. M., Mangana, J., Levesque, M. P. and Dummer, R. (2016). An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel. British Journal of Dermatology, 175 (5), 966-978. doi: 10.1111/bjd.14727
Diem, Stefan, Keller, Fabienne, Ruesch, Reinhard, Maillard, Samia A., Speiser, Daniel E., Dummer, Reinhard, Siano, Marco, Urner-Bloch, Ursula, Goldinger, Simone M. and Flatz, Lukas (2016). Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. Journal of Immunotherapy, 39 (9), 379-382. doi: 10.1097/CJI.0000000000000143
Urner-Bloch, U., Urner, M., Jaberg-Bentele, N., Frauchiger, A. L., Dummer, R. and Goldinger, S. M. (2016). MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects. European Journal of Cancer, 65, 130-138. doi: 10.1016/j.ejca.2016.06.018
Goldinger, Simone M., Stieger, Pascale, Meier, Barbara, Micaletto, Sara, Contassot, Emmanuel, French, Lars E. and Dummer, Reinhard (2016). Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy. Clinical Cancer Research, 22 (16), 4023-4029. doi: 10.1158/1078-0432.CCR-15-2872
Goldinger, Simone M., Bischof, Sharon Gobbi, Fink-Puches, Regina, Klemke, Claus-Detlev, Dreno, Brigitte, Bagot, Martine and Dummer, Reinhard (2016). Efficacy and Safety of AP0866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial. Jama Dermatology, 152 (7), 837-839. doi: 10.1001/jamadermatol.2016.0401
Hofmann, Lars, Forschner, Andrea, Loquai, Carmen, Goldinger, Simone M., Zimmer, Lisa, Ugurel, Selma, Schmidgen, Maria I., Gutzmer, Ralf, Utikal, Jochen S., Goeppner, Daniela, Hassel, Jessica C., Meier, Friedegund, Tietze, Julia K., Thomas, Ioannis, Weishaupt, Carsten, Leverkus, Martin, Wahl, Renate, Dietrich, Ursula, Garbe, Claus, Kirchberger, Michael C., Eigentler, Thomas, Berking, Carola, Gesierich, Anja, Krackhardt, Angela M., Schadendorf, Dirk, Schuler, Gerold, Dummer, Reinhard and Heinzerling, Lucie M. (2016). Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer, 60, 190-209. doi: 10.1016/j.ejca.2016.02.025
Zimmer, Lisa, Goldinger, Simone M., Hofmann, Lars, Loquai, Carmen, Ugurel, Selma, Thomas, Ioannis, Schmidgen, Maria I., Gutzmer, Ralf, Utikal, Jochen S., Goeppner, Daniela, Hassel, Jessica C., Meier, Friedegund, Tietze, Julia K., Forschner, Andrea, Weishaupt, Carsten, Leverkus, Martin, Wahl, Renate, Dietrich, Ursula, Garbe, Claus, Kirchberger, Michael C., Eigentler, Thomas, Berking, Carola, Gesierich, Anja, Krackhardt, Angela M., Schadendorf, Dirk, Schuler, Gerold, Dummer, Reinhard and Heinzerling, Lucie M. (2016). Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European Journal of Cancer, 60, 210-225. doi: 10.1016/j.ejca.2016.02.024
Henning, Benjamin, Stieger, Pascale, Kamarachev, Jivko, Dummer, Reinhard and Goldinger, Simone M. (2016). Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation. Melanoma Research, 26 (3), 304-307. doi: 10.1097/CMR.0000000000000248
Frauchiger, A. L., Mangana, J., Rechsteiner, M., Moch, H., Seifert, B., Braun, R. P., Dummer, R. and Goldinger, S. M. (2016). Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. British Journal of Dermatology, 174 (4), 823-830. doi: 10.1111/bjd.14347
Goldinger, Simone M., Panje, Cedric and Nathan, Paul (2016). Treatment of melanoma brain metastases. Current Opinion in Oncology, 28 (2), 159-165. doi: 10.1097/CCO.0000000000000270
Kunz, M., Urosevic-Maiwald, M., Goldinger, S. M., Frauchiger, A. L., Dreier, J., Belloni, B., Mangana, J., Jenni, D., Dippel, M., Cozzio, A., Guenova, E., Kamarachev, J., French, L. E. and Dummer, R. (2016). Efficacy and safety of oral alitretinoin in severe oral lichen planus - results of a prospective pilot study. Journal of the European Academy of Dermatology and Venereology, 30 (2), 293-298. doi: 10.1111/jdv.13444
Goldinger, Simone M., Dummer, Reinhard, Baumgaertner, Petra, Mihic-Probst, Daniela, Schwarz, Katrin, Hammann-Haenni, Anya, Willers, Joerg, Geldhof, Christine, Prior, John O., Kuendig, Thomas M., Michielin, Olivier, Bachmann, Martin F. and Speiser, Daniel E. (2016). Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients (vol 42, pg 3049, 2012). European Journal of Immunology, 46 (2), 493-493. doi: 10.1002/eji.201670027
Del Prete, Valerio, Chaloupka, Karla, Holzmann, David, Fink, Daniel, Levesque, Mitchell, Dummer, Reinhard and Goldinger, Simone M. (2016). Noncutaneous Melanomas: A Single-Center Analysis. Dermatology, 232 (1), 22-29. doi: 10.1159/000441444
Johnson, Douglas B., Menzies, Alexander M., Zimmer, Lisa, Eroglu, Zeynep, Ye, Fei, Zhao, Shilin, Rizos, Helen, Sucker, Antje, Scolyer, Richard A., Gutzmer, Ralf, Gogas, Helen, Kefford, Richard F., Thompson, John F., Becker, Juergen C., Berking, Carola, Egberts, Friederike, Loquai, Carmen, Goldinger, Simone M., Pupo, Gulietta M., Hugo, Willy, Kong, Xiangju, Garraway, Levi A., Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S., Long, Georgina V. and Schadendorf, Dirk (2015). Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 51 (18), 2792-2799. doi: 10.1016/j.ejca.2015.08.022
Van Allen, Eliezer M., Miao, Diana, Schilling, Bastian, Shukla, Sachet A., Blank, Christian, Zimmer, Lisa, Sucker, Antje, Hillen, Uwe, Foppen, Marnix H. Geukes, Goldinger, Simone M., Utikal, Jochen, Hassel, Jessica C., Weide, Benjamin, Kaehler, Katharina C., Loquai, Carmen, Mohr, Peter, Gutzmer, Ralf, Dummer, Reinhard, Gabriel, Stacey, Wu, Catherine J., Schadendorf, Dirk and Garraway, Levi A. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 350 (6257), 207-211. doi: 10.1126/science.aad0095
Mangana, Joanna, Cheng, Phil F., Schindler, Katja, Weide, Benjamin, Held, Ulrike, Frauchiger, Anna L., Romano, Emanuella, Kaehler, Katharina C., Rozati, Sima, Rechsteiner, Markus, Moch, Holger, Michielin, Olivier, Garbe, Claus, Hauschild, Axel, Hoeller, Christoph, Dummer, Reinhard and Goldinger, Simone M. (2015). Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. Plos One, 10 (10) e0139438. doi: 10.1371/journal.pone.0139438
Matsushita, Shigeto, Kraehenbuehl, Lukas, Otsuka, Atsushi, Mihic-Probst, Daniela, Cheng, Phil, Dummer, Reinhard and Goldinger, Simone M. (2015). Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma. Journal of Dermatology, 42 (9), 927-928. doi: 10.1111/1346-8138.12964
Ribas, Antoni, Puzanov, Igor, Dummer, Reinhard, Schadendorf, Dirk, Hamid, Omid, Robert, Caroline, Hodi, F. Stephen, Schachter, Jacob, Pavlick, Anna C., Lewis, Karl D., Cranmer, Lee D., Blank, Christian U., O'Day, Steven J., Ascierto, Paolo A., Salama, April K. S., Margolin, Kim A., Loquai, Carmen, Eigentler, Thomas K., Gangadhar, Tara C., Carlino, Matteo S., Agarwala, Sanjiv S., Moschos, Stergios J., Sosman, Jeffrey A., Goldinger, Simone M., Shapira-Frommer, Ronnie, Gonzalez, Rene, Kirkwood, John M., Wolchok, Jedd D., Eggermont, Alexander ... Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16 (8), 908-918. doi: 10.1016/S1470-2045(15)00083-2
Hecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., Forschner, A., Clemens, P., Grabenbauer, G., Mueller-Brenne, T., Bauch, J., Eich, H. T., Grabbe, S., Schadendorf, D., Schuler, G., Keikavoussi, P., Semrau, S., Fietkau, R., Distel, L. V. and Heinzerling, L. (2015). Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Annals of Oncology, 26 (6), 1238-1244. doi: 10.1093/annonc/mdv139
Galliker, Nadja A., Murer, Carla, Kamarashev, Jivko, Dummer, Reinhard and Goldinger, Simone M. (2015). Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. European Journal of Dermatology, 25 (2), 177-180. doi: 10.1684/ejd.2014.2512
Goldinger, Simone M., Rinderknecht, Jeannine, Dummer, Reinhard, Kuhn, Felix Pierre, Yang, Kuo-Hsiung, Lee, Lucy, Ayala, Ruben C., Racha, Jagdish, Geng, Wanping, Moore, David, Liu, Mei, Joe, Andrew K., Bazan, Selby Patricia Gil and Grippo, Joseph F. (2015). A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma. Pharmacology Research & Perspectives, 3 (2) e00113. doi: 10.1002/prp2.113
Dummer, Reinhard, Goldinger, Simone M., Paulitschke, Verena and Levesque, Mitchell P. (2015). Curing advanced melanoma by 2025. Current Opinion in Oncology, 27 (2), 125-127. doi: 10.1097/CCO.0000000000000168
Cheng, Phil F., Shakhova, Olga, Widmer, Daniel S., Eichhoff, Ossia M., Zingg, Daniel, Frommel, Sandra C., Belloni, Benedetta, Raaijmakers, Marieke I. G., Goldinger, Simone M., Santoro, Raffaella, Hemmi, Silvio, Sommer, Lukas, Dummer, Reinhard and Levesque, Mitchell P. (2015). Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology, 16 42. doi: 10.1186/s13059-015-0594-4
Dreier, J., Cheng, P. F., Alleman, I. Bogdan, Gugger, A., Hafner, J., Tschopp, A., Goldinger, S. M., Levesque, M. P. and Dummer, R. (2014). Basal cell carcinomas in a tertiary referral centre: a systematic analysis. British Journal of Dermatology, 171 (5), 1066-1072. doi: 10.1111/bjd.13217
Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E. A., Rozati, S., Eggmann, N., Goldinger, S. M., Hutchinson, K., Geskin, L., Illidge, T. M., Giuliano, E., Elder, J. and Kim, Y. H. (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome). Annals of Oncology, 25 (9), 1807-1812. doi: 10.1093/annonc/mdu231
Urner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Moutouh-de Parseval, L., Dummer, R. and Goldinger, S. M. (2014). Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Annals of Oncology, 25 (7), 1437-1441. doi: 10.1093/annonc/mdu169
Dummer, Reinhard, Goldinger, Simone M., Widmer, Daniel, Dreier, Jil and Levesque, Mitchell P. (2014). To B-(RAF) or Not to Be. Journal of Investigative Dermatology, 134 (5), 1200-1201. doi: 10.1038/jid.2014.62
Schilling, B., Sondermann, W., Zhao, F., Griewank, K. G., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kahler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2014). Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Annals of Oncology, 25 (3), 747-753. doi: 10.1093/annonc/mdt587
Dummer, Reinhard, Goldinger, Simone M., Turtschi, Christian P., Eggmann, Nina B., Michielin, Olivier, Mitchell, Lada, Veronese, Luisa, Hilfiker, Paul Rene, Felderer, Lea and Rinderknecht, Jeannine D. (2014). Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. European Journal of Cancer, 50 (3), 611-621. doi: 10.1016/j.ejca.2013.11.002
Van Allen, Eliezer M., Wagle, Nikhil, Sucker, Antje, Treacy, Daniel J., Johannessen, Cory M., Goetz, Eva M., Place, Chelsea S., Taylor-Weiner, Amaro, Whittaker, Steven, Kryukov, Gregory V., Hodis, Eran, Rosenberg, Mara, McKenna, Aaron, Cibulskis, Kristian, Farlow, Deborah, Zimmer, Lisa, Hillen, Uwe, Gutzmer, Ralf, Goldinger, Simone M., Ugurel, Selma, Gogas, Helen J., Egberts, Friederike, Berking, Carola, Trefzer, Uwe, Loquai, Carmen, Weide, Benjamin, Hassel, Jessica C., Gabriel, Stacey B., Carter, Scott L. ... Schadendorf, Dirk (2014). The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma. Cancer Discovery, 4 (1), 94-109. doi: 10.1158/2159-8290.CD-13-0617
Goldinger, Simone M., Zimmer, Lisa, Schulz, Carsten, Ugurel, Selma, Hoeller, Christoph, Kaehler, Katharina C., Schadendorf, Dirk, Hassel, Jessica C., Becker, Juergen, Hauschild, Axel and Dummer, Reinhard (2014). Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 50 (2), 406-410. doi: 10.1016/j.ejca.2013.09.014
Rinderknecht, Jeannine D., Goldinger, Simone M., Rozati, Sima, Kamarashev, Jivko, Kerl, Katrin, French, Lars E., Dummer, Reinhard and Belloni, Benedetta (2013). RASopathic Skin Eruptions during Vemurafenib Therapy. Plos One, 8 (3) e58721. doi: 10.1371/journal.pone.0058721
Raaijmakers, Marieke I. G., Rozati, Sima, Goldinger, Simone M., Widmer, Daniel S., Dummer, Reinhard and Levesque, Mitchell P. (2013). Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy, 5 (2), 169-182. doi: 10.2217/IMT.12.162
Voskens, Caroline J., Goldinger, Simone M., Loquai, Carmen, Robert, Caroline, Kaehler, Katharina C., Berking, Carola, Bergmann, Tanja, Bockmeyer, Clemens L., Eigentler, Thomas, Fluck, Michael, Garbe, Claus, Gutzmer, Ralf, Grabbe, Stephan, Hauschild, Axel, Hein, Ruediger, Hundorfean, Gheorghe, Justich, Armin, Keller, Ullrich, Klein, Christina, Mateus, Christine, Mohr, Peter, Paetzold, Sylvie, Satzger, Imke, Schadendorf, Dirk, Schlaeppi, Marc, Schuler, Gerold, Schuler-Thurner, Beatrice, Trefzer, Uwe, Ulrich, Jens ... Heinzerling, Lucie M. (2013). The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. Plos One, 8 (1) e53745. doi: 10.1371/journal.pone.0053745
Goldinger, Simone M., Dummer, Reinhard, Baumgaertner, Petra, Mihic-Probst, Daniela, Schwarz, Katrin, Hammann-Haenni, Anya, Willers, Joerg, Geldhof, Christine, Prior, John O., Kuendig, Thomas M., Michielin, Olivier, Bachmann, Martin F. and Speiser, Daniel E. (2012). Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients. European Journal of Immunology, 42 (11), 3049-3061. doi: 10.1002/eji.201142361
Dummer, R., Rozati, S., Eggmann, N., Rinderknecht, J. and Goldinger, S. M. (2012). From chemotherapy to targeted treatment. Annals of Oncology, 23, 101-103. doi: 10.1093/annonc/mds308
Zimmer, Lisa, Hillen, Uwe, Livingstone, Elisabeth, Lacouture, Mario E., Busam, Klaus, Carvajal, Richard D., Egberts, Friederike, Hauschild, Axel, Kashani-Sabet, Mohammed, Goldinger, Simone M., Dummer, Reinhard, Long, Georgina V., McArthur, Grant, Scherag, Andre, Sucker, Antje and Schadendorf, Dirk (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology, 30 (19), 2375-2383. doi: 10.1200/JCO.2011.41.1660
Dummer, Reinhard, Goldinger, Simone M., Cozzio, Antonio, French, Lars E. and Karpova, Maria B. (2012). Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs. Journal of Investigative Dermatology, 132 (3), 517-525. doi: 10.1038/jid.2011.370
Dummer, Reinhard, Rinderknecht, Jeannine and Goldinger, Simone M. (2012). Ultraviolet A and Photosensitivity during Vemurafenib Therapy. New England Journal of Medicine, 366 (5), 480-481. doi: 10.1056/NEJMc1113752
von Moos, R., Seifert, B., Simcock, M., Goldinger, S. M., Gillessen, S., Ochsenbein, A., Michielin, O., Cathomas, R., Schlaeppi, M., Moch, H., Schraml, P. H., Mjhic-Probst, D., Mamot, C., Schoenewolf, N. and Dummer, R. (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology, 23 (2), 531-536. doi: 10.1093/annonc/mdr126
Belloni, Benedetta, Schoenewolf, Nicola, Rozati, Sima, Goldinger, Simone M. and Dummer, Reinhard (2012). Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs. Adverse Cutaneous Drug Eruptions, 97, 191-202.
Imhof, Laurence, Goldinger, Simone M., Baumann, Katrin, Schad, Karin, French, Lars E., Roethlisberger, Peter and Dummer, Reinhard (2011). The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. Melanoma Research, 21 (1), 80-83. doi: 10.1097/CMR.0b013e328341442d
Strobel, K., Bode, B., Dummer, R., Veit-Haibach, P., Fischer, D. R., Imhof, L., Goldinger, S., Steinert, Hans C. and von Schulthess, G. K. (2009). Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 36 (11), 1774-1782. doi: 10.1007/s00259-009-1175-0
Goldinger, S. M., Dummer, R., Schmid, P., Burg, G., Seifert, B. and Lauchli, S. (2007). Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. Journal of the European Academy of Dermatology and Venereology, 21 (4), 504-508. doi: 10.1111/j.1468-3083.2006.02016.x
Goldinger, Simone Maria, Dummer, Reinhard, Schmid, Peter, Vavricka, Mareike Prinz, Burg, Guenter and Laeuchli, Severin (2006). Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris. Dermatology, 213 (2), 134-139. doi: 10.1159/000093852
Conference Papers
Pham, J. P., Hurwitz, J., Cosman, R., Goldinger, S. M., Sim, H. W., Dummer, R. and Joshua, A. M. (2023). Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and metaanalysis. Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.2261
Goldinger, Simone M., Lo, Serigne, Hassel, Jessica Cecile, Forschner, Andrea, McKean, Meredith Ann, Zimmer, Lisa, Khoo, Chloe Chia Hoey, Dummer, Reinhard, Eroglu, Zeynep, Buchbinder, Elizabeth Iannotti, Ascierto, Paolo Antonio, Gutzmer, Ralf, Rozeman, Elisa A., Hoeller, Christoph, Johnson, Douglas Buckner, Gesierich, Anja, Kolblinger, Peter, Benannoune, Naima, Cohen, Justine Vanessa and Menzies, Alexander M. (2018). The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2018.36.15_suppl.e21588
Rai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Koo, C., Park, J. J., Ardolino, L., Yip, D., Goldinger, S., Cohen, J. V., Millward, M., Atkinson, V., Kane, A. Y., Ascierto, P. A., Garbe, C., Gutzmer, R., Johnson, D. B., Hellman, M. D., Long, G. V. and Menzies, A. M. (2017). Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS.
Dimitriou, F., Frauchiger, A., Goldinger, S. M., Braun, R., Mangana, J. and Dummer, R. (2017). Sarcoid-like reactions under modern melanoma treatment. HOBOKEN: WILEY.
Schindler, S., Courtier, A., Jaberg-Bentele, N., Goldinger, S., Manuel, M., Perez, S., Mouret, J. -F., Nguyen-Kim, T. D. L., Raaijmakers, M., Kvistborg, P., Pasqua, N., Haanen, J., Dummer, R. and Levesque, M. (2017). The peripheral blood TCR repertoire might facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma. HOBOKEN: WILEY.
Kaufmann, C., Mangana, J., Cheng, P., Ramelyte, E., Goldinger, S. M., Levesque, M. P. and Dummer, R. (2017). Thin melanoma in Swiss Patients: A clinicopathological comparison. HOBOKEN: WILEY.
Goldinger, Simone M., Graf, Natalie P., Galliker, Nadja, Conrad, Samuel and Dummer, Reinhard (2017). Hyperproliferative keratinocytic cutaneous adverse events and inflammatory palmoplantar erythrodysesthesia in melanoma patients treated with encorafenib compared to other BRAF inhibitors. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-06, 2017. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2017.35.15_suppl.9590
da Silva, Ines Esteves Domingues Pires, Johnpulle, Romany Anne Nilanthi, Banks, Patricia Diana, Grass, G. Daniel, Smith, Jess Louise, Everett, Ashlyn S., Goldinger, Simone M., -Thomson, Rachel Roberts, Millward, Michael, Glitza, Isabella Claudia, Haydu, Lauren Elaine, Atkinson, Victoria, Wang, Tim, Eroglu, Zeynep, Conry, Robert Martin, Shackleton, Mark J., Hong, Angela, Long, Georgina V., Johnson, Douglas Buckner and Menzies, Alexander M. (2017). Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1). 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-07, 2017. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2017.35.15_suppl.9513
Valpione, Sara, Carlino, Matteo S., Mangana, Joanna, Mooradian, Meghan, McArthur, Grant A., Schadendorf, Dirk, Hauschild, Axel, Long, Georgina V., Arance, Ana M., Ascierto, Paolo Antonio, Maio, Michele, De Rosa, Francesco, Larkin, James M. G., Park, John J., Goldinger, Simone M., Flaherty, Keith, Xu, Wen, Livingstone, Elisabeth, Weichenthal, Michael and Lorigan, Paul (2017). Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-07, 2017. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2017.35.15_suppl.9512
Dummer, R., Michielin, O. A., Nageli, M., Goldinger, S. M., Campigotto, F., Kriemler-Krahn, U., Schmid, H., Pedroncelli, A., Micaletto, S. and Schadendorf, D. (2016). A phase I, open-label study of pasireotide in patients with BRAF-and NRAS-wild type, unresectable and or metastatic melanoma. OXFORD: OXFORD UNIV PRESS. doi: 10.1093/annonc/mdw379.43
Krahenbuhl, L., Goldinger, S. M., Kerl, K., Kempf, W., Chevolet, I., Brochez, L., Cheng, P., Mangana, J., Levesque, M. P. and Dummer, R. (2016). Systemic treatment influences on immune accessibility of melanoma: A retrospective histopathological investigation. OXFORD: OXFORD UNIV PRESS. doi: 10.1093/annonc/mdw379.28
Haueis, S., Kranzlin, P., Cheng, P., Mangana, J., Dummer, R. and Goldinger, S. (2016). Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?. HOBOKEN: WILEY-BLACKWELL.
Thurneysen, S., Cheng, P. F., Nagel, H. W., Kunz, M., Jaberg-Bentele, N., Naegeli, M., Guenova-Hotzenecker, E., Goldinger, S., Mangana, J., Levesque, M. P. and Dummer, R. (2016). An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxel. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Haueis, S., Kranzlin, P., Cheng, P. F., Mangana, J., Dummer, R. and Goldinger, S. M. (2016). Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Mangana, J., Amann, V. C., Goldinger, S. M., Kaufmann, C., Frauchiger, A. L., Cheng, P., Stoegner, V., Held, U., Von Moos, R., Romano, E., Michielin, O., Braun, R., Levesque, M. P. and Dummer, R. (2016). Multi-center real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Schadendorf, D., Michielin, O., Nageli, M., Goldinger, S. M., Campigotto, F., Kriemler-Krahn, U., Schmid, H. A., Pedroncelli, A. M., Micaletto, S. and Dummer, R. (2016). Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma: a phase I, open-label, single-arm study. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Urosevic-Maiwald, M., Goldinger, S. M., Sommerauer, M., Dummer, R. and Schaefer, N. G. (2016). The value of PET/CT patterns in response prediction of metastasized melanoma treated with ipilimumab. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Goldinger, Simone M., Tsai, Katy K., Tumeh, Paul, Hamid, Omid, Nosrati, Adi, Loo, Kimberly, Grimes, Barbara, Algazi, Alain Patrick, Levesque, Mitchell P., Dummer, Reinhard and Daud, Adil (2016). Correlation between metastatic site and response to anti-Programmed Death-1 (PD-1) agents in melanoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 03-07, 2016. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2016.34.15_suppl.9549
Nosrati, Adi, Goldinger, Simone M., Tsai, Katy K., Loo, Kimberly, Tumeh, Paul, Hamid, Omid, Algazi, Alain Patrick, Levesque, Mitchell P., Dummer, Reinhard and Daud, Adil (2016). Derivation and validation of a prediction scale for response to PD-1 monotherapy. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 03-07, 2016. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2016.34.15_suppl.9514
Goldinger, Simone M., Courtier, Anais, Jaberg-Bentele, Nicoletta F., Schindler, Sabrina, Manuel, Manuarii, Plantier, Nadia, Treillard, Bertrand, Noel, Marlene, Thi Dan Linh Nguyen-Kim, , Raaijmakers, Marieke Ineke Geertje, Kvistborg, Pia, Haanen, John B. A. G., Dummer, Reinhard and Levesque, Mitchell (2016). The peripheral blood TCR repertoire to facilitate patient stratification for immune checkpoint blockade inhibition in metastatic melanoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 03-07, 2016. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2016.34.15_suppl.3026
Cosgarea, I., Franklin, C., Schwamborn, M., Sucker, A., Griewank, K. G., Weide, B., Loquai, C., Hassel, J. C., Kaehler, K. C., Utikal, J., Gutzmer, R., Goldinger, S. M., Paschen, A., Schadendorf, D. and Schilling, B. (2016). A distinct role for eosinophil and neutrophil granulocytes in patients with advanced melanoma receiving selective BRAF inhibitors. 43rd Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung-e-V (ADF), Vienna Austria, Mar 10-12, 2016. HOBOKEN: WILEY-BLACKWELL.
Hecht, M., Zimmer, L., Loquai, C., Weishaupt, C., Gutzmer, R., Schuster, B., Gleisner, S., Schulze, B., Goldinger, S. M., Berking, C., Forschner, A., Clemens, P., Grabenbauer, G., Mueller-Brenne, T., Bauch, J., Eich, H. T., Grabbe, S., Schadendorf, D., Schuler, G., Keikavoussi, P., Semrau, S., Fietkau, R., Distel, L. V. and Heinzerling, L. (2015). Radio Sensitization through BRAF Inhibitors- Mechanism and Frequency of Toxicities in Melanoma patients. 21st Annual Meeting of the German-Society-for-Radiation-Oncology, Hamburg Germany, Jun 25-28, 2015. MUNICH: URBAN & VOGEL.
Goldinger, Simone M., Gobbi, Sharon, Ding, Michelle, Frauchiger, Anna Lisa, Fink-Puches, Regina, Klemke, Claus-Detlev, Dreno, Brigitte, Bagot, Martine, Assaf, Chalid and Dummer, Reinhard (2015). A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.
Brueggemann, Caroline, Weide, Benjamin, Goldinger, Simone M., Konrad, Andreas, Erdmann, Michael, Schadendorf, Dirk, Croner, Roland S., Kraehenbuehl, Lukas, Kaehler, Katharina C., Hafner, Christian, Leisgang, Waltraud, Kiesewetter, Franklin, Dummer, Reinhard, Schuler, Gerold, Stuerzl, Michael and Heinzerling, Lucie (2015). Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.
Goldinger, Simone M., Mangana, Joanna, Frauchiger, Anna L., Kaufmann, Corina, Held, Ulrike, Von Moos, Roger, Romano, Emanuela, Michielin, Olivier, Levesque, Mitchell Paul and Dummer, Reinhard (2015). Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago Il, May 29-Jun 02, 2015. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.
Kunz, Michael, Urosevic-Maiwald, Mirjana, Cozzio, Antonio, Dippel, Michaela, Dreier, Jil, French, Lars E., Goldinger, Simone, Guenova, Emmanuella, Jenni, Daniella, Kamarachev, Jivko, Mangana, Johanna and Dummer, Reinhard (2015). Efficacy and safety of oral alitretinoin in oral mucosal lichen planus-results of a prospective trial. NEW YORK: MOSBY-ELSEVIER.
Cosgarea, I., Sondermann, W., Livingstone, E., Griewank, K., Weide, B., Loquai, C., Hassel, J., Kaehler, K. C., Utikal, J., Al Ghazal, P., Gutzmer, R., Goldinger, S. M., Schadendorf, D., Zimmer, L. and Schilling, B. (2014). Association of leukocyte counts and adverse events in BRAF inhibitor-treated patients. HOBOKEN: WILEY-BLACKWELL.
Schilling, B., Sondermann, W., Zhao, F., Griewank, K., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J. C., Kaehler, K. C., Utikal, J., Al Ghazal, P., Gutzmar, R., Goldinger, S. M., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2014). Differential influence of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical efficacy in melanoma. 41st Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung (ADF), Cologne Germany, Mar 13-15, 2014. HOBOKEN: WILEY.
Schilling, B., Suttorp, W., Zhao, F., Griewank, K., Livingstone, E., Sucker, A., Zelba, H., Weide, B., Trefzer, U., Wilhelm, T., Loquai, C., Berking, C., Hassel, J., Kaehler, K., Utikal, J., Gutzmer, R., Al Ghazal, P., Goldinger, S., Zimmer, L., Paschen, A., Hillen, U. and Schadendorf, D. (2013). Differential effects of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical effectivity in melanoma. HOBOKEN: WILEY-BLACKWELL.
Murer, C., Goldinger, S. M., Maggio, Marques E., Bjasch, D., Stieger, P., Mihic-Probst, D., Schad, K. and Dummer, R. (2013). Hyponatraemia and Tachyarrhythmia During Ipilimumab: Lessons from the Autopsy. HOBOKEN: WILEY-BLACKWELL.
Mangana, J., Frauchiger, A., Goldinger, S. M., Gautschi, M., Von Moos, R., Romano, E., Michielin, O., Levesque, M. P. and Dummer, R. (2013). Registry for advanced melanoma in Switzerland. HOBOKEN: WILEY-BLACKWELL.
Mangana, Joanna, Goldinger, Simone M., Schindler, Katja, Rozati, Sima, Frauchiger, Anna L., Rechsteiner, Markus, Moch, Holger, Romano, Emanuela, Kaehler, Katharina C., Michielin, Olivier, Hauschild, Axel, Hoeller, Christoph and Dummer, Reinhard (2013). Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Van Allen, Eliezer Mendel, Wagle, Nikhil, Carter, Scott L., Sucker, Antje, Farlow, Deborah Norman, Hodis, Fran, Taylor-Weiner, Amara, Berking, Carola, Egberts, Friederike, Hassel, Jessica Cecile, Gogas, Helen, Gutzmer, Ralf, Goldinger, Simone M., Loquai, Carmen, Ugurel, Selma, Zimmer, Lisa, Gabriel, Stacey B., Getz, Gad, Garraway, Levi A. and Schadendorf, Dirk (2013). The genetic landscape of clinical resistance to RAF inhibition in melanoma. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Goldinger, Simone M., Murer, Carla, Stieger, Pascale and Dummer, Reinhard (2013). Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Heinzerling, L., Goldinger, S. M., Voskens, C. J., Loquai, C., Robert, C., Berking, C., Eigentler, T., Fluck, M., Garbe, C., Gutzmer, R., Gleiss, H., Hauschild, A., Hein, R., Justich, A., Keller, U., Klein, C., Mateus, C., Mohr, P., Paetzold, S., Satzger, , Schadendorf, D., Schlaeppi, M., Ulrich, J., Vaubel, J., von Moos, R., Weder, P., Wilhelm, T., Kaehler, K., Goeppner, D. ... Schuler, G. (2013). The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. HOBOKEN: WILEY-BLACKWELL.
Dummer, R., Goldinger, S., Turtschi, C., Eggmann, N., Michielin, O., Mitchell, L., Veronese, L., Hilfiker, P. R. and Rinderknecht, J. D. (2012). OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM). 37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna Austria, Sep 28-Oct 02, 2012. OXFORD: OXFORD UNIV PRESS.
Goldinger, Simone M., Rinderknecht, Jeannine Desiree, Belloni, Benedetta, Eggmann, Nina and Dummer, Reinhard (2012). Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.
Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E., Goldinger, S., Hutchinson, K., Geskin, L., Illidge, T., Kim, Y., Giuliano, E. and Elder, J. (2011). Final results of single-agent phase II study using the inhibitor of purine nucleoside phosphorylase (PNP) in patients suffering from advanced primary cutaneous t-cell lymphomas (CTCL). MALDEN: WILEY-BLACKWELL.
Dummer, R., Goldinger, S., Turtschi, C., Gisler, S., Eggmann, N. and Rinderknecht, J. (2011). Inhibition of the MEK-kinase pathway in advanced melanoma. BASEL: KARGER.
Dummer, R., Rinderknecht, J., Goldinger, S. M., Wagner, I., Mitchell, L., Veronese, M. L., Nick, S., Hilfiker, P. and Gobbi, S. (2011). An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2011.29.15_suppl.8548
Dummer, R., Michielin, O., Seifert, B., Ochsenbein, A. F., Cathomas, R., Schlaeppi, M. R., Simcock, M., Gillessen, S., Goldinger, S. M. and von Moos, R. (2010). First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2010.28.15_suppl.8521
Fuerstenberger, G., Boneberg, E., Simcock, M., Dummer, R., Goldinger, S. M., Michielin, O., Seifert, B., Ochsenbein, A. F., Schlaeppi, M. R. and von Moos, R. (2010). Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2010.28.15_suppl.8585
Von Moos, R., Seifert, B., Ochsenbein, A., Cathomas, R., Schlaeppi, M., Gillessen, S., Schuller, J. C., Michielin, O., Goldinger, S. and Dummer, R. (2009). Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07). 15th ECCO/34th ESMO Multidisciplinary Congress, Berlin Germany, Sep 20-24, 2009. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. doi: 10.1016/S1359-6349(09)72059-2